Fig. 4

Kaplan-Meier curves for overall survival based on the protein expressions. A Patients with early-stage tumors expressing high vs. low Wip1 (n=18 vs. 84). B Patients with early-stage tumors expressing positive vs. negative p53 (n=21 vs. 81). C Patients with early-stage tumors expressing high vs. low phospho-p53 (n=57 vs. 45). D Patients with early-stage tumors expressing high vs. low nuclear phospho-p38 (n=50 vs. 52). E Patients with early-stage tumors expressing high vs. low cytoplasmic phospho-p38 (n=9 vs. 93). F Patients with advanced-stage tumors expressing high vs. low Wip1 (n=5 vs. 36). G Patients with advanced-stage tumors expressing positive vs. negative p53 (n=14 vs. 27). H Patients with advanced-stage tumors expressing high vs. low phospho-p53 (n=38 vs. 3). I Patients with advanced-stage tumors expressing high vs. low nuclear phospho-p38 (n=38 vs. 3). J Patients with advanced-stage tumors expressing high vs. low cytoplasmic phospho-p38 (n=30 vs. 11). OS, overall survival